Precigen (PGEN) Non Operating Investment Income (2012 - 2025)

Precigen's (PGEN) quarterly Non Operating Investment Income came in at -$111.5 million in Q3 2025, down 2600.04% on a QoQ basis from $4.5 million in Q2 2025.

Precigen (PGEN) Non Operating Investment Income (2012 - 2025) Analysis & Trends

Precigen (PGEN) has 5 years of Non Operating Investment Income data on file, last reported at -$111.5 million in Q3 2025.

  • On a quarterly basis, Non Operating Investment Income changed N/A year-over-year to -$111.5 million in Q3 2025; TTM through Mar 2026 was -$107.0 million, a 229.55% decrease from a year earlier, with the FY2025 full-year figure at -$139.5 million, changed N/A from the prior year.
  • Non Operating Investment Income for Q3 2025 stood at -$111.5 million, down from $4.5 million in the prior quarter.
  • Over the last five years, Non Operating Investment Income for PGEN reached as high as $4.5 million in Q2 2025 and fell as low as -$111.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Precigen 1.95 Bn 1.95 Bn 20.69 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 -111.50 Mn
Sep 30, 2025 -111.50 Mn
Jun 30, 2025 4.46 Mn
Jun 30, 2025 4.46 Mn
Mar 31, 2025 -32.48 Mn
Mar 31, 2025 -32.48 Mn
Mar 31, 2016 -22.33 Mn
Mar 31, 2016 -22.33 Mn
Mar 31, 2015 115.45 Mn
Mar 31, 2015 115.45 Mn
Mar 31, 2013 7.42 Mn
Mar 31, 2013 7.42 Mn
Dec 31, 2012 -7.40 Mn
Dec 31, 2012 -7.40 Mn